All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YC0156 | Human anti-C12H18N4O7 T cell receptor (#4), pCDTCR1 | Salmonella enterica subsp. enterica serovar Typhimurium | #4 | Human | reduced 6-(hydroxymethyl)-8-(1-D-ribityl)lumazine | human MR1 | Lentiviral vector | |
TCR-YC0157 | Human anti-C12H18N4O7 T cell receptor (#4 (TRAJ20)), pCDTCR1 | #4 (TRAJ20) | Human | 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil | human MR1 | Lentiviral vector | ||
TCR-YC0158 | Human anti-C12H18N4O7 T cell receptor (#6 (TRBV6-4)), pCDTCR1 | #6 (TRBV6-4) | Human | 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil | human MR1 | Lentiviral vector | ||
TCR-YC0159 | Human anti-C12H18N4O7 T cell receptor (AE6), pCDTCR1 | E. coli | AE6 | Human | reduced 6-(hydroxymethyl)-8-(1-D-ribityl)lumazine | hbMR1 | Lentiviral vector | |
TCR-YC0160 | Human anti-C12H18N4O7 T cell receptor ((A-F7)-1), pCDTCR1 | A-F7 | Human | 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil | human MR1 | Lentiviral vector | ||
TCR-YC0161 | Human anti-C12H18N4O7 T cell receptor ((A-F7)-2), pCDTCR1 | Salmonella enterica subsp. enterica serovar Typhimurium | A-F7 | Human | reduced 6-(hydroxymethyl)-8-(1-D-ribityl)lumazine | human MR1 | Lentiviral vector | |
TCR-YC0162 | Human anti-C12H18N4O7 T cell receptor (B-B10), pCDTCR1 | B-B10 | Human | 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil | MR1 | Lentiviral vector | ||
TCR-YC0163 | Human anti-C12H18N4O7 T cell receptor (B-C10), pCDTCR1 | B-C10 | Human | 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil | MR1 | Lentiviral vector | ||
TCR-YC0164 | Human anti-C12H18N4O7 T cell receptor ((B-F3-C1)-1), pCDTCR1 | B-F3-C1 | Human | 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil | MR1 | Lentiviral vector | ||
TCR-YC0165 | Human anti-C12H18N4O7 T cell receptor ((B-F3-C1)-2), pCDTCR1 | Salmonella enterica subsp. enterica serovar Typhimurium | B-F3-C1 | Human | reduced 6-(hydroxymethyl)-8-(1-D-ribityl)lumazine | human MR1 | Lentiviral vector | |
TCR-YC0166 | Human anti-C12H18N4O7 T cell receptor ((B-G8)-1), pCDTCR1 | B-G8 | Human | 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil | human MR1 | Lentiviral vector | ||
TCR-YC0167 | Human anti-C12H18N4O7 T cell receptor ((B-G8)-2), pCDTCR1 | Salmonella enterica subsp. enterica serovar Typhimurium | B-G8 | Human | reduced 6-(hydroxymethyl)-8-(1-D-ribityl)lumazine | human MR1 | Lentiviral vector | |
TCR-YC0168 | Human anti-C12H18N4O7 T cell receptor (C-A11), pCDTCR1 | C-A11 | Human | 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil | human MR1 | Lentiviral vector | ||
TCR-YC0169 | Human anti-C12H18N4O7 T cell receptor (C-C10), pCDTCR1 | C-C10 | Human | 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil | human MR1 | Lentiviral vector | ||
TCR-YC0170 | Human anti-C12H18N4O7 T cell receptor (C-F7), pCDTCR1 | C-F7 | Human | 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil | human MR1 | Lentiviral vector | ||
TCR-YC0171 | Human anti-C12H18N4O7 T cell receptor (F7), pCDTCR1 | E. coli | F7 | Human | reduced 6-(hydroxymethyl)-8-(1-D-ribityl)lumazine | hbMR1 | Lentiviral vector | |
TCR-YC0172 | Human anti-C12H18N4O7 T cell receptor (G2), pCDTCR1 | E. coli | G2 | Human | reduced 6-(hydroxymethyl)-8-(1-D-ribityl)lumazine | hbMR1 | Lentiviral vector | |
TCR-YC0173 | Human anti-C12H18N4O7 T cell receptor (M33.64), pCDTCR1 | M33.64 | Human | 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil | human MR1 | Lentiviral vector | ||
TCR-YC0174 | Human anti-C12H18N4O7 T cell receptor (M33.64(Y95F)), pCDTCR1 | M33.64(Y95F) | Human | 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil | human MR1 | Lentiviral vector | ||
TCR-YC0175 | Human anti-C12H18N4O7 T cell receptor (MAV36), pCDTCR1 | MAV36 | Human | 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil | human MR1 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION